Ironwood and Allergan Report Positive Results of Inzess (linaclotide) in P-IIIb Trial for Patients with Irritable Bowel Syndrome with Constipation
Shots:
- The P-IIIb study results involve assessing of Inzess (290 mcg- qd) vs PBO in 614 adult patients on multiple abdominal symptoms with IBS-C
- The P-III study results met its 1EPs & 2EPs demonstrating overall improvement in abdominal symptoms of bloating- pain and discomfort in adults- decrease in weekly abdominal score 29.7% vs 18.3%; clinically meaningful response (40.5% vs 23.4%); diarrhea (4.6% vs 1.6%)
- Linaclotide is a guanylate cyclase-C (GC-C) agonist binds to GC-C receptor locally- approved in the US for IBS-C or chronic idiopathic constipation (CIC) and is marketed in EU for moderate to severe IBS-C with brand name Constella
Ref: Ironwood | Image: Occam Global
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com